Questions, answered straight
Ipamorelin: the questions people actually ask, answered from the record.
Direct answers, cited where the claim is quantitative — on what ipamorelin does, what it doesn't, and where the human evidence runs out.
What does ipamorelin do for you?
Ipamorelin releases a pulse of growth hormone by activating the ghrelin receptor (GHS-R1a) on the pituitary. Its distinctive trait is doing so cleanly: in its founding characterization it released growth hormone potently in rat pituitary cells, rats, and swine (swine ED50 2.3 nmol/kg) without raising cortisol [1]. What that translates to for any individual has not been established in controlled human outcome trials.
Does ipamorelin increase IGF-1?
Sometimes, but not reliably in short studies. Growth hormone normally drives the liver to make IGF-1, yet in a 15-day rat bone-growth study, dose-dependent skeletal effects occurred with no measurable change in total IGF-1 [4]. CJC-1295, the GHRH analog often paired with ipamorelin, produces more durable IGF-1 elevation [7]. So IGF-1 response depends on the protocol and the timeframe.
What does ipamorelin peptide do?
The ipamorelin peptide (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) tells the pituitary to release a single growth-hormone pulse by mimicking ghrelin at the GHS-R1a receptor [1]. It is the selectivity that defines it — strong growth-hormone release without the cortisol and prolactin bump seen with older GHRPs [1]. Beyond that pulse, its broader effects in people remain largely uncharacterized in controlled trials.
Does ipamorelin build muscle?
No controlled human trial has shown ipamorelin builds muscle. The supporting evidence is preclinical and indirect: the ipamorelin-derived oral analog NN703 produced body-weight gain in rats over 14 days [10], and a 2026 review reported the CJC-1295 + ipamorelin combination improved muscle tetanic tension in a mouse muscle-loss model [14]. Reported lean-mass changes in community use are anecdotal and confounded by diet and training.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide — a five-amino-acid chain — and the first highly selective growth hormone secretagogue, characterized in 1998 [1]. It activates the ghrelin/GHS-R1a receptor to release growth hormone without meaningfully raising ACTH, cortisol, or prolactin [1]. Developed by Novo Nordisk as NNC 26-0161, it was later trialed for postoperative ileus and never approved as a drug.
What is ipamorelin peptide?
Ipamorelin peptide is a wholly synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective ghrelin-receptor agonist, releasing a growth-hormone pulse [1]. It is not an endogenous human peptide — it mimics ghrelin's action at GHS-R1a. Its non-natural Aib residue at position 1 increases resistance to enzymatic breakdown, which is part of why it is more stable than some earlier GHRPs.
What are the risks of ipamorelin?
The documented risks are mostly unknowns. The one human efficacy trial (NCT00672074, n=114) found no ipamorelin-specific safety signal over 7 days but also missed its endpoint [3]. The larger concerns are long-term and class-level: a 28-day study of a related GHS-R1a agonist found heart-muscle damage in rats [6], and GH-axis stimulation raises theoretical IGF-1/cancer questions [4]. Long-term human safety is uncharacterized.
Does ipamorelin reduce belly fat?
No human trial has tested ipamorelin for belly fat. The relevant animal data are about weight defense, not fat loss: a 2024 ferret study found intraperitoneal ipamorelin (1–3 mg/kg) inhibited cisplatin-induced body-weight loss by about 24% during the delayed phase [5]. Community reports of a gradually leaner look are anecdotal and confounded by concurrent diet and training [4].
What are the downsides of ipamorelin?
The biggest downside is the evidence gap: one human efficacy trial, and it failed [3]. Beyond that, community-reported nuisances include post-injection facial flushing, mild water retention, tingling, increased appetite, and a fading response over months — all anecdotal. The class-level cardiac signal from a related agonist [6] and the absence of long-term human safety data are the substantive concerns.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved product to discontinue, but its clinical development effectively stopped because its only Phase 2 trial failed: in postoperative ileus (NCT00672074, n=114), it missed its primary endpoint (25.3 h vs 32.6 h to first tolerated meal, p=0.15) [3]. Separately, in 2024 the FDA narrowed compounding-pharmacy access by removing ipamorelin acetate from the interim 503A Category 2 list.
What does CJC-1295 and ipamorelin do?
Together they aim to raise growth hormone through two doors at once: ipamorelin fires a ghrelin-receptor pulse [1], while CJC-1295, a long-acting GHRH analog, sustains the GH/IGF-1 axis with more durable IGF-1 elevation [7]. The pairing logic is complementary mechanisms. There is no controlled human trial of the combination for any outcome — only single-agent pharmacology.
How does CJC-1295 ipamorelin work?
The combination works by hitting two different receptors. Ipamorelin activates the ghrelin/GHS-R1a receptor to trigger a discrete growth-hormone pulse [1]; CJC-1295 activates the GHRH receptor to raise baseline GH/IGF-1 axis tone [7]. Because the pathways are distinct and complementary, the growth-hormone-releasing effects can add together — which is the rationale behind pairing a short-acting GHRP with a long-acting GHRH analog.
How much CJC-1295 ipamorelin should I take?
No published source supports a human dose, and this site does not provide one. Community subcutaneous 'stack' protocols have no peer-reviewed human dosing basis, and the combination itself has never been tested in a controlled human trial [7]. The only solid dosing-adjacent figures are single-agent pharmacokinetics — ipamorelin's ~2-hour half-life and 40-minute pulse [2]. Anyone facing a real decision should consult a qualified professional.
Does CJC-1295 ipamorelin work?
Each peptide works pharmacologically — ipamorelin releases a growth-hormone pulse [1] and CJC-1295 raises IGF-1 [7] — but the combination's marketed outcomes have not been demonstrated in any controlled human trial. The nearest evidence is a preclinical muscle-tension improvement in a mouse model reported in a 2026 review [14]. Pharmacologically active; clinically unproven for the combination.
How to reconstitute CJC-1295 ipamorelin 5mg?
Ipamorelin is supplied as a lyophilized (freeze-dried) powder and, in research handling, reconstituted with bacteriostatic water; as a peptide it degrades with heat and freeze-thaw and is generally refrigerated [2]. These are general research-supply handling notes, not a clinical preparation instruction. No validated human-use reconstitution protocol exists for a combination product, because no such product is approved.
How long does ipamorelin stay in your system?
Ipamorelin clears quickly. In healthy human volunteers, its terminal half-life is about 2 hours (IV), with clearance of 0.078 L/h/kg, and the growth-hormone response peaks near 40 minutes as a single pulse [2]. Practically, the parent peptide is largely gone within several hours, though the downstream growth-hormone pulse it triggers plays out on its own timeline.
Does ipamorelin make you hungry?
It can, because it acts on the ghrelin (hunger) receptor. Community reports describe increased appetite in the hours after injection, generally milder than with GHRP-6, though anecdotal [9]. Mechanistically this fits: ghrelin-receptor agonism is tied to appetite, and ipamorelin's growth-hormone selectivity does not remove the receptor-level orexigenic signal.
Will I gain weight on ipamorelin?
There is no human trial answering this. Preclinically, the ipamorelin-derived analog NN703 caused body-weight gain in rats over 14 days [10], and the parent compound's ghrelin-receptor action can increase appetite [9]. Community accounts vary between leaner body composition and fluid-related puffiness — all anecdotal and confounded. The single 7-day human trial did not report weight gain as a signal [3].
Does ipamorelin increase appetite?
Yes, increased appetite is a class-level effect of ghrelin-receptor agonists, and ipamorelin is one. In diabetic mice, ipamorelin produced strong growth-hormone hypersecretion [9], and the receptor it uses governs hunger signaling. Community users report an appetite uptick after dosing, described as milder than GHRP-6 but real for some — anecdotal, not a controlled finding.
How long does it take for ipamorelin to work?
Pharmacologically, fast: the growth-hormone pulse peaks near 40 minutes after a dose in human PK studies [2]. For the subjective effects people chase — sleep, recovery — community reports describe onset within one to two weeks, but those are anecdotal and unverified. The acute hormone response and the perceived longer-term effects are on very different timescales.
Does ipamorelin cause water retention?
Some community users report mild, transient water retention — puffiness in fingers, ankles, or face — usually in the first two to four weeks and often described as milder than with older GHRPs; this is anecdotal [3]. Mechanistically, growth-hormone elevation is associated with sodium and water retention, which makes the reports plausible, though no controlled ipamorelin study has quantified it.
Where to inject CJC-1295 ipamorelin?
This site does not give injection instructions. For reference only: in the research literature, subcutaneous administration was the dominant route in rodent body-composition studies and in community use [4], while human trials used intravenous infusion [2]. Describing where studies administered a compound is not a directive to inject anything; no approved combination product or human-use protocol exists.